Drug Type Tregs cell therapy |
Synonyms- |
Target- |
Action modulators |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Graft Versus Host Disease | Phase 2 | United States | 16 Feb 2017 | |
Acute Myeloid Leukemia | Phase 2 | United States | 16 Feb 2017 | |
Burkitt Lymphoma | Phase 2 | United States | 16 Feb 2017 | |
Chronic Lymphocytic Leukemia | Phase 2 | United States | 16 Feb 2017 | |
Chronic Myelogenous Leukemia | Phase 2 | United States | 16 Feb 2017 | |
Lymphoplasmacytic Lymphoma | Phase 2 | United States | 16 Feb 2017 | |
Mantle-Cell Lymphoma | Phase 2 | United States | 16 Feb 2017 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | United States | 16 Feb 2017 | |
Multiple Myeloma | Phase 2 | United States | 16 Feb 2017 | |
Myelodysplastic Syndromes | Phase 2 | United States | 16 Feb 2017 |
Phase 2 | Acute Myeloid Leukemia | Lymphoplasmacytic Lymphoma | Acute Graft Versus Host Disease | Chronic Lymphocytic Leukemia | Acute Lymphoblastic Leukemia | Hematologic Neoplasms | Neoplasms | Acute Biphenotypic Leukemia | Burkitt Lymphoma | Mantle-Cell Lymphoma | Follicular Lymphoma | Multiple Myeloma | Large Granular Lymphocytic Leukemia | Prolymphocytic Leukemia | Marginal Zone B-Cell Lymphoma | Small Lymphocytic Lymphoma | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes | 3 | vbhuuziosc(jrgwiokkbn) = enzykoqxhm wanimldvir (ygkujdzjvw, oxerdwlpel - qyjokqwgub) View more | - | 24 Jul 2020 |